Tag: FDA

Some opioid addiction drugs harder to start than others, study finds

Image License Photo: FDA 14 NOV 17 19:19 ET By Nadia Kounang, CNN (CNN) — The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine. Buprenorphine is commonly known by the the brand name Suboxone, and naltrexone is sold under the brand name Vivitrol. The study, published Tuesday in the┬áLancet, looked at 570 patients with opioid addiction at eight inpatient treatment centers across the country for 24 weeks....

Read More

Kratom has ‘deadly risks,’ FDA warns

Image License Photo: Jessica Mullen / CC BY 2.0 License Link 14 NOV 17 15:42 ET By Nadia Kounang and Sandee LaMotte, CNN (CNN) — The Food and Drug Administration dealt another blow Tuesday to supporters of kratom, warning about “deadly risks” associated with the botanical supplement often used to treat pain, anxiety and depression. Kratom also has opioid-like effects — at low doses, it acts like a stimulant; at higher doses, it sedates, dulling pain — which has also made it popular as an over-the-counter remedy for opioid withdrawal. “It’s very troubling to the FDA that patients believe...

Read More

Papaya Recall after salmonella outbreak

United States (KFXV) — 47 cases,12 hospitalizations and one death in 12 states all connected to a Salmonella outbreak in papayas. The Food and Drug Administration has announced a recall of papayas distributed by a local produce company. According to the FDA, they are currently investigating a Salmonella outbreak they say stems from “Caribena” branded papayas from Mexico distributed by Grande Produce, a produce company in San Juan, Texas. They also note that the outbreak also includes states where the Grande Produce Company does not distribute in. Caribena papayas sold between July 10 through 19th should be immediately disposed...

Read More

FDA Approves 1st Drug For Aggressive Multiple Sclerosis

BY LINDA A. JOHNSON TRENTON, N.J. (AP) — U.S. regulators have approved the first drug for an aggressive kind of multiple sclerosis that steadily reduces coordination and the ability to walk. The Food and Drug Administration approved Ocrevus late Tuesday after a large study found it slowed progression of the neurological disease and reduced symptoms. While there are more than a dozen treatments for the most common form of MS, there’s been nothing specifically for people with the type called primary progressive MS. That type of MS is relatively rare, affecting about 50,000 Americans. The drug was also approved...

Read More

FDA issues warning about risky vein opening procedure

BY LINDA A. JOHNSON TRENTON, N.J. (AP) — The Food and Drug Administration on Wednesday again warned patients and doctors to avoid a risky, experimental procedure promoted as a treatment for several nervous system disorders, including multiple sclerosis and Parkinson’s disease. The procedure involves inflating a tiny balloon in narrowed veins, usually in the neck, to widen them and improve blood flow. The FDA said it has seen no evidence the procedure – called transvascular autonomic modulation, or TVAM – is safe or effective. It’s similar to balloon angioplasty, which is commonly used to open up clogged heart arteries....

Read More